CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Findings to be presented at upcoming scientific conference and submitted for publication
30, September 2025 – CHOSA Today announced positive results from its collaboration with international lung cancer experts in the European Thoracic Oncology Platform (ETOP IBCSG Partners Foundation) and the European Organisation for Research and Treatment of Cancer (EORTC). The project evaluates CHOSA’s Drug Response Predictor (Platin-DRP®) in patients with advanced non-small cell lung cancer (NSCLC) treated in the SPLENDOUR trial.
Following rigorous curation of tumor tissue, the analysis included 28 patients treated with cisplatin and 54 with carboplatin. For cisplatin, the Platin-DRP® reached its primary endpoint and showed statistically significant prediction of Progression-Free Survival (PFS) with higher PFS associated with higher Platin-DRP®, overall and across two of the three thresholds tested. Overall Survival (OS) demonstrated no significant association in this limited sample size.
For carboplatin - the sister molecule of cisplatin - the Platin-DRP® showed statistically significant prediction of Overall Survival with higher OS associated with higher Platin-DRP®, overall and across all tested Platin-DRP® thresholds. In addition, a positive trend was observed for prediction of PFS.
These findings support and extend prior validation of the Platin-DRP® in-licensed from Allarity Therapeutics Inc., including two retrospective NSCLC studies and one prospective metastatic breast cancer study. In addition, CHOSA will in October present new carboplatin breast cancer data at ESMO in Berlin. Taken together, they represent important steps toward regulatory approval and integration into treatment guidelines. We will now initiate interactions with the FDA and EMA to explore a path towards marketing approval.
“Platinum compounds remain the backbone of therapy in advanced NSCLC, yet there are no biomarkers allowing to predict their efficacy in clinical use today,” said Professors Solange Peters and Rolf Stahel, ETOP lung cancer experts. “The CHOSA collaboration provides preliminary support for the potential of Platin-DRP® in daily practice.”
“Lung cancer remains one of the deadliest cancers worldwide. This project demonstrates that our predictor can identify patients more likely to benefit from cisplatin or carboplatin,” said Peter Buhl Jensen, MD, DMSc, CEO of CHOSA. “The ability to leverage high-quality biopsies from a large, independent trial has saved us years of development and brought us significantly closer to commercialization.”
CHOSA expects to present the full data at upcoming scientific conference and will submit the results for peer-reviewed publication.
The SPLENDOUR trial (PubMed ID: 32565388) included 514 patients with advanced NSCLC receiving platinum-based therapy.
For additional information, contact
Peter Buhl Jensen, CEO
Peter@chosa.bio
+ 45 21 60 89 22
About the SPLENDOUR trial
In the SPLENDOUR trial, 514 patients with advanced lung cancer received cisplatin- or carboplatin -based therapy. Τumor samples from 28 cisplatin-treated and 54 carboplatin-treated patients were available from ETOP and met quality criteria for platinum sensitivity analysis. This enables CHOSA to leverage biopsies from an already completed, high-quality study and, in a highly cost-effective manner, obtain independent blinded valuable clinical data to support commercialization. Platinum drugs are used in nearly all treatments of lung cancer, and CHOSA has assessed the accuracy of the Pllatin-DRP® in predicting tumor response to cisplatin or carboplatin chemotherapy. The study was designed to generate pivotal data to support CHOSA’s test in clinical guidelines and regulatory approval.
The project is being conducted in collaboration with the ETOP IBCSG Partners Foundation and the European Organisation for Research and Treatment of Cancer (EORTC), together with SPLENDOUR trial lung cancer experts Professor Solange Peters and Professor Rolf Stahel. The tumor tissue analyses were performed at Allarity’s laboratories. The resulting data were then processed by CHOSA using the Platin-DRP®, where they were stratified into three likelihood levels of treatment response. These predictions were subsequently sent to ETOP, where they were linked to blinded clinical outcomes of the individual patients.
The SPLENDOUR trial is described at https://pubmed.ncbi.nlm.nih.gov/32565388/
About ETOP IBCSG Partners Foundation
The ETOP IBCSG Partners Foundation is a not-for-profit international academic research organization based in Berne, Switzerland. Established on July 1, 2021, through the merger of the European Thoracic Oncology Platform (ETOP) and the International Breast Cancer Study Group (IBCSG), the foundation aims to promote scientific exchange and advance cancer research, particularly in thoracic and breast cancers.
The foundation's mission is to answer questions that improve patients' lives, with a vision of enhancing scientific exchange on a global scale. It achieves this by implementing and promoting clinical and translational research studies, fostering collaboration among international investigators, and organizing educational events such as annual meetings and residential workshops.
About EORTC
The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.
Background
Cisplatin and its sister compound carboplatin are mainstays of lung cancer therapy. Even with advances in immunotherapy, platinum drugs remain essential components of treatment regimens, including combinations with PD-1/L1 inhibitors as Keytruda and Opdivo and newer dual-binder immunotherapies. Surprising synergy between platin and PD-1/PD-L1 products have been shown repeatedly, and they are now the mainstay in lung cancer treatment. While having revolutionized lung cancer therapy, only 50% benefit from these new platinum combination therapies. Numerous studies have been focused on predicting the effect of immunotherapy with limited success. While many attempts to predict cisplatin efficacy have failed, the Platin-DRP®—a 205-gene biomarker signature—has demonstrated promising results in other settings, including improved outcomes in adjuvant NSCLC therapy and progression-free survival in breast cancer.
This study explored the predictive potential of the Platin-DRP® not only in cisplatin-treated patients but also in those treated with carboplatin. The SPLENDOUR trial provided a unique opportunity to validate this tool in a well-characterized cohort, potentially confirming its clinical utility across both platinum drugs. Future research will investigate whether the Platin-DRP® can also predict benefit from platinum–PD-1/L1 inhibitor combinations.
CHOSA in short
CHOSA Oncology AB is a precision oncology biotechnology company developing Drug Response Predictor (DRP®) tests to personalize chemotherapy and improve patient outcomes. By matching the right patient with the right drug, CHOSA aims to extend survival and reduce unnecessary toxicity across multiple cancer types.
The company is led by an experienced international team of specialists in oncology, drug development, clinical trials, regulatory strategy, and business development. CHOSA also intends to enter into agreements for partnerships or sublicensing of LiPlaCis® and the DRP®.
About Platin-DRP® also referred to as LiPlaCis DRP®, a 205 gene test to predict if platin treatment is likely to be successful
CHOSA is focused on late-stage clinical development of LiPlaCis® and its DRP® drug response predictor to which it has worldwide rights. The Platin-DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin and carboplatin. Breast: We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by Platin-DRP® responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment. In addition, CHOSA will in October 2025 present new carboplatin breast cancer data at ESMO in Berlin.
Lung: The Platin-DRP has now shown its ability in three studies of lung cancer to foresee the value of platin therapy in lung cancer. Cisplatin / carboplatin therapy is a gold standard that increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin or carboplatin and who should have something else. This is where the Platin-DRP® is a potential game changer, especially in new neoadjuvant treatment where immunotherapy obtains high efficacy rates when combined with platin doublets.
Immunotherapy There is a new development that adds further value to our DRP. Cisplatin has often been shown to activate the immune system (making cold tumors hot), which makes tumors susceptible to PD1 inhibitors. This synergy is particularly important but not limited to the treatment of lung cancer, bladder cancer, and head and neck cancer. In the ever-growing PD1 inhibitor market, where competition is fierce, our company stands out with the ability to predict if cisplatin will provide synergy with PD1. This can give the PD1 selling companies a significant competitive advantage.
DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics, Inc., (previous Oncology Venture ApS) and LiPlasome Pharma ApS.